References
- Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. Pathology and Genetics of Tumors of the Lung, Pleura, Thymus, and Heart, 4th ed. Lyon, France: International Agency for Research on Cancer Press; 2015.
- Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: Guideline from the college of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med. 2018; 142(3): 321-346.
- Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014; 20(5): 548-554.
- Thompson JC, Yee SS, Troxel AB, Savitch SL, Fan R, Balli D, et al. Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next-generation sequencing of cell-free circulating tumor DNA. Clin Cancer Res. 2016; 22(23): 5772-5782.
- Schwaederlé MC, Patel SP, Husain H, Ikeda M, Lanman RB, Banks KC, et al. Utility of genomic assessment of blood-derived circulating tumor DNA (ctDNA) in patients with advanced lung adenocarcinoma. Clin Cancer Res. 2017; 23(17): 5101-5111.
- Sawada K, Kotani D, Bando H. The clinical landscape of circulating tumor DNA in gastrointerstinal malignancies. 2018; 8: 263. doi: 10.3389/fonc.2018.00263. eCol lection 2018.
- Esposito AR, Pasquale R, Fenizia F, Rachiglio AM, Roma C, Bergantino F, et al. The role of circulating free DNA in the management of NSCLC. Expert Rev Anticancer Ther. 2019; 19(1): 19-28.
- Uchida J, Kato K, Kukita Y, Kumagai T, Nishino K, Daga H, et al. Diagnostic accuracy of non invasive genotyping of EGFR in lung cancer patients by deep sequencing of plasma cell-free DNA. Clin Chem. 2015; 61(9): 1191-1196.
- Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-celllung cancer. N Engl J Med. 2005; 353(2): 123-132.
- Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomized, placebo controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2004; 366(9496): 1527-1537.
- Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13(3): 239-246.
- Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in nonsmall-cell lung cancer. N Engl J Med. 2010; 363(18): 1693-1703.
- Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland Å, et al. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: An open-label, phase 2 trial. Lancet Oncol. 2017; 18(10): 1307-1316.
- Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, et al. Non-small cell lung cancer, version 6.2015. J Natl Compr Canc Netw. 2015; 13(5): 515-524.
- Mok T, Wu YL, Lee JS, Yu CJ, Sriuranpong V, Sandoval-Tan J, et al. Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib. Clin Cancer Res. 2015; 21(14): 3196-3203.
- Douillard JY, Ostoros G, Cobo M, Ciuleanu T, Cole R, McWalter G, et al. Gefitinib treatment in EGFR mutated caucasian NSCLC: Circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol. 2014; 9(9): 1345-1353.
- Reck M, Hagiwara K, Han B, Tjulandin S, Grohé C, Yokoi T, et al. ctDNA determination of EGFR mutation status in European and Japanese patients with advanced NSCLC: The ASSESS study. J Thorac Oncol. 2016; 11(10): 1682-1689.
- Dearden S, Stevens J, Wu YL, Blowers D. Mutation incidence and coincidence in non small-cell lung cancer: Meta-analyses by ethnicity and histology (mutMap). Ann Oncol. 2013; 24(9): 2371-2376.
- Zhang X-C, Wang J, Shao G-G, Wang Q, Qu X, Wang B, et al. Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients. Nat Commun. 2019; 10(1): 1772.
- Song Z, Wang H, Yu Z, Lu P, Xu C, Chen G, et al. De novo MET amplification in Chinese patients with non-small-cell lung cancer and treatment efficacy with crizotinib: A multicenter retrospective study. Clin Lung Cancer. 2018; 20(2)): e 171-e176.
- Asao T, Takahashi F, Takahashi K. Resistance to molecularly targeted therapy in non-small-cell lung cancer. Respir Investig. 2019; 57(1): 20-26. doi: 10.1016/j.resinv. 2018.09.001. Epub 2018 Oct 4.
- Konduri K, Gallant JN, Chae YK, Giles FJ, Gitlitz BJ, Gowen K, et al. EGFR fusions as novel therapeutic targets in lung cancer. Cancer Discov. 2016; 6(6): 601-611.
- Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017; 376(7): 629-640.
- Rolfo C, Giovannetti E, Hong DS, Bivona T, Raez LE, Bronte G, et al. Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors. Cancer Treatment Rev. 2014; 40(8): 990-1004.
- Linda K, Mikael J, Kjell G, Jonas N. Liquid biopsies in lung cancer — time to implement research technologies in routine care? Ann Transl Med. 2017; 5(13): 278.